MX2017007243A - Metodos para desarrollo y uso de unidades micro-agregadas de celulas funcionales polarizadas minimamente en aplicaciones en tejidos utilizando celulas troncales epiteliales que expresan lgr4, lgr5 y lgr6. - Google Patents

Metodos para desarrollo y uso de unidades micro-agregadas de celulas funcionales polarizadas minimamente en aplicaciones en tejidos utilizando celulas troncales epiteliales que expresan lgr4, lgr5 y lgr6.

Info

Publication number
MX2017007243A
MX2017007243A MX2017007243A MX2017007243A MX2017007243A MX 2017007243 A MX2017007243 A MX 2017007243A MX 2017007243 A MX2017007243 A MX 2017007243A MX 2017007243 A MX2017007243 A MX 2017007243A MX 2017007243 A MX2017007243 A MX 2017007243A
Authority
MX
Mexico
Prior art keywords
applications
lgr4
lgr5
development
methods
Prior art date
Application number
MX2017007243A
Other languages
English (en)
Inventor
M Lough Denver
Original Assignee
Polarityte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56078499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017007243(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polarityte Inc filed Critical Polarityte Inc
Publication of MX2017007243A publication Critical patent/MX2017007243A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

Se proporcionan en la presente estructuras de injertos micro-agregados multicelulares, polarizados mínimamente, que contienen células que expresan el Receptor acoplado a la proteína G que contienen una repetición rica en leucina (LGR) para aplicaciones en terapia de heridas, diseño por ingeniería de tejidos, aplicaciones en terapia celular, aplicaciones en medicina regenerativa, aplicaciones médicas/terapéuticas, aplicaciones en curación de tejidos, aplicaciones en terapia inmunológica, y aplicaciones en terapia para trasplante de tejidos que de preferencia están asociadas con un vector/sustrato/soporte/andamio de suministro para aplicación directa.
MX2017007243A 2014-12-02 2015-12-01 Metodos para desarrollo y uso de unidades micro-agregadas de celulas funcionales polarizadas minimamente en aplicaciones en tejidos utilizando celulas troncales epiteliales que expresan lgr4, lgr5 y lgr6. MX2017007243A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086526P 2014-12-02 2014-12-02
US14/954,335 US10926001B2 (en) 2014-12-02 2015-11-30 Methods related to minimally polarized functional units
PCT/US2015/063114 WO2016089825A1 (en) 2014-12-02 2015-12-01 Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells

Publications (1)

Publication Number Publication Date
MX2017007243A true MX2017007243A (es) 2018-01-25

Family

ID=56078499

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017007243A MX2017007243A (es) 2014-12-02 2015-12-01 Metodos para desarrollo y uso de unidades micro-agregadas de celulas funcionales polarizadas minimamente en aplicaciones en tejidos utilizando celulas troncales epiteliales que expresan lgr4, lgr5 y lgr6.
MX2023001655A MX2023001655A (es) 2014-12-02 2017-06-05 Composiciones que comprenden celulas troncales que expresan lgr y usos de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001655A MX2023001655A (es) 2014-12-02 2017-06-05 Composiciones que comprenden celulas troncales que expresan lgr y usos de las mismas.

Country Status (21)

Country Link
US (7) US10926001B2 (es)
EP (1) EP3227431A4 (es)
JP (3) JP6791854B2 (es)
KR (5) KR20170098844A (es)
CN (1) CN107250348B (es)
AU (3) AU2015355187C1 (es)
BR (1) BR112017011808A2 (es)
CA (1) CA2969707C (es)
CO (1) CO2017006640A2 (es)
CR (1) CR20170296A (es)
EA (1) EA201791125A1 (es)
GB (2) GB2549872A (es)
HK (2) HK1250515A1 (es)
IL (2) IL252613B (es)
MX (2) MX2017007243A (es)
MY (1) MY184931A (es)
NZ (2) NZ755260A (es)
PH (1) PH12017501009B1 (es)
SG (2) SG10201914058QA (es)
WO (1) WO2016089825A1 (es)
ZA (1) ZA201703907B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3743125A4 (en) * 2018-01-26 2022-03-02 Polarityte, Inc. BIOMATERIAL ACCELERATING SUBSTRATE WITH COMPOSITE INTERFACE
AU2019212976A1 (en) * 2018-01-26 2020-07-23 Polarityte, Inc. Complex living interface-coordinated self-assembling materials (CLICSAM)
FR3082123B1 (fr) 2018-06-07 2020-10-16 Urgo Rech Innovation Et Developpement Pansement cellularise et son procede de fabrication

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126881A1 (en) * 2002-09-06 2004-07-01 Vincent Ronfard Fibrin cell supports and methods of use thereof
WO2006008009A2 (en) 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6)
WO2006026617A2 (en) 2004-08-30 2006-03-09 Iken Tissue Therapeutics, Inc. Compositions and methods of promoting hair growth
WO2007048831A2 (en) * 2005-10-27 2007-05-03 Coloplast A/S Biodegradable scaffold with ecm material
WO2008008009A1 (en) 2006-07-13 2008-01-17 St. Jude Medical Ab Medical information management in a patient information hub system
US8366723B2 (en) 2006-08-03 2013-02-05 Rassman Licensing, Llc Hair harvesting device and method with localized subsurface dermal fluid insertion
EP2066787A1 (en) 2006-09-12 2009-06-10 DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts Cell culture of keratinocytes under non-differentiating conditions
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
FI20095355A0 (fi) 2009-04-01 2009-04-01 Helsingin Yliopisto Regeneroituva aktiivinen matriisi ja sen käytöt
TW201110973A (en) 2009-06-25 2011-04-01 Shiseido Co Ltd Methods for screening for anti-graying agents on the basis of AFF-4
US20110130711A1 (en) 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
KR20130041103A (ko) 2010-06-30 2013-04-24 진시 첸 피부조직세포 응집체의 제조방법과 및 그 용도
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
AU2012328353B2 (en) 2011-10-27 2017-05-25 Universitat Leipzig Method for deriving melanocytes from the hair follicle outer root sheath and preparation for grafting
JP6186997B2 (ja) 2012-08-07 2017-08-30 日油株式会社 塗布型帯電防止剤
US9655930B2 (en) 2012-10-01 2017-05-23 Aderans Research Institute, Inc. Compositions and methods for producing reconstituted skin
US20140106447A1 (en) 2012-10-12 2014-04-17 Mimedx Group, Inc. Compositions and methods for recruiting stem cells
HUE049377T2 (hu) 2013-03-14 2020-09-28 Brigham & Womens Hospital Inc Készítmények és eljárások epiteliális õssejtek expanziójára és tenyésztésére
US9592257B2 (en) 2013-10-11 2017-03-14 MWV Cell, LLC Complete human skin organ generated from culture-expanded cells
CN103550828B (zh) * 2013-10-17 2016-01-27 中国科学院动物研究所 一种基于毛囊干细胞和硅凝胶敷料的皮肤重建方法
TWI548413B (zh) 2014-11-07 2016-09-11 國立臺灣大學 誘導毛囊新生的皮膚萃取物、組合物及其用途

Also Published As

Publication number Publication date
US11596714B2 (en) 2023-03-07
GB201902819D0 (en) 2019-04-17
AU2019240603A1 (en) 2019-10-17
US11266765B2 (en) 2022-03-08
EA201791125A1 (ru) 2018-06-29
NZ755260A (en) 2021-12-24
PH12017501009A1 (en) 2017-12-11
CO2017006640A2 (es) 2017-11-21
AU2015355187A1 (en) 2017-06-29
CN107250348B (zh) 2021-09-03
US11000629B2 (en) 2021-05-11
CN107250348A (zh) 2017-10-13
GB2549872A (en) 2017-11-01
HK1250515A1 (zh) 2018-12-21
AU2015355187C1 (en) 2020-02-20
NZ733433A (en) 2019-08-30
GB2569056A (en) 2019-06-05
US20190046691A1 (en) 2019-02-14
PH12017501009B1 (en) 2017-12-11
AU2023202857A1 (en) 2023-05-25
BR112017011808A2 (pt) 2018-02-27
CR20170296A (es) 2018-01-25
US20230181797A1 (en) 2023-06-15
KR20190111167A (ko) 2019-10-01
JP2017538411A (ja) 2017-12-28
US20160151540A1 (en) 2016-06-02
GB2569056B (en) 2020-01-01
IL287488A (en) 2021-12-01
JP2020182880A (ja) 2020-11-12
KR20210043024A (ko) 2021-04-20
KR20180136587A (ko) 2018-12-24
US20220241464A1 (en) 2022-08-04
US20210322643A1 (en) 2021-10-21
US20180154044A1 (en) 2018-06-07
ZA201703907B (en) 2023-03-29
KR20170098844A (ko) 2017-08-30
SG10201914058QA (en) 2020-03-30
KR20180136588A (ko) 2018-12-24
WO2016089825A1 (en) 2016-06-09
MY184931A (en) 2021-04-30
EP3227431A4 (en) 2019-01-02
AU2015355187B2 (en) 2019-10-03
US10926001B2 (en) 2021-02-23
HK1245327A1 (zh) 2018-08-24
EP3227431A1 (en) 2017-10-11
CA2969707A1 (en) 2016-06-09
US11338060B2 (en) 2022-05-24
CA2969707C (en) 2019-08-20
JP2019088299A (ja) 2019-06-13
IL287488B2 (en) 2023-06-01
IL252613A0 (en) 2017-07-31
SG11201704502RA (en) 2017-06-29
IL252613B (en) 2021-12-01
AU2019240603B2 (en) 2023-02-09
MX2023001655A (es) 2023-04-24
GB201710646D0 (en) 2017-08-16
JP6791854B2 (ja) 2020-11-25
US20180154043A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
PH12015500115A1 (en) Glucagon analogues
PH12017500164A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MX2019012849A (es) Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
MX2023001655A (es) Composiciones que comprenden celulas troncales que expresan lgr y usos de las mismas.
EP3234107A4 (en) B cells for in vivo delivery of therapeutic agents
PH12018501237A1 (en) Isoindole compounds
MX2017005484A (es) Compuestos antagonistas del receptor de dopamina d3.
IL274691A (en) Transformed human cells inhibited for expression of mhc i and mhc ii cell membrane receptors and uses thereof
EA201691596A1 (ru) Составы гепарина для наружного применения
AR096092A1 (es) ANTICUERPOS ANTI-IGF-1R CON ABOLICIÓN DE LA UNIÓN AL FcRn Y SU UTILIZACIÓN EN EL TRATAMIENTO DE ENFERMEDADES OCULARES VASCULARES